Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | GRM5 | P41594 | 2/20 | 0.47 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | CCR8 | P51685 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | GBA1 | P04062 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30558522 | 0.81 | — | — | |
| SCHEMBL306134 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL6363468 | 0.79 | RAB9A (0.55) | RAB9AMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL229747 | 0.78 | RAB9A (0.59) | RAB9AMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL30754820 | 0.74 | — | — | |
| SCHEMBL19915750 | 0.74 | — | — | |
| SCHEMBL10138645 | 0.74 | — | — | |
| SCHEMBL2007460 | 0.74 | — | — | |
| SCHEMBL20003708 | 0.74 | — | — | |
| SCHEMBL4316235 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975853-B2 | Tetrahydroisoquinolinone derivatives and their use in the inhibition of the HSP70 protein | JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURG (DE) | 2018-05-22 | — | — | US | disclosed |
| US-20170152229-A1 | TETRAHYDROISOQUINOLINONE DERIVATIVES AND THEIR USE IN THE INHIBITION OF THE HSP70 PROTEIN | JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURG (DE) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152229-A1 | TETRAHYDROISOQUINOLINONE DERIVATIVES AND THEIR USE IN THE INHIBITION OF THE HSP70 PROTEIN | HSPH1, HSP90AB1, HSP90AB2P | RAB9A 2087/4885MEN1 4303/4885KMT2A 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.